<DOC>
	<DOC>NCT00604396</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to investigate the safety and efficacy of insulin detemir combined with oral anti-diabetic drugs (OADs) versus insulin NPH combined with oral anti-diabetic drugs (OADs) in Type 2 mellitus not well controlled on current therapy on blood glucose control.</brief_summary>
	<brief_title>Safety and Efficacy of Insulin Detemir in Combination With OAD in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin, beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Isophane Insulin, Human</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Type 2 diabetes for at least 12 months since diagnosis Insulin naive subjects OAD treatment for at least 4 months alone or combined with no more than two OADs Body mass index (BMI) below 35.0 kg/m2 HbA1c between 7.510.0% Able and willing to use twice a day injections for the entire trial period Current or previous treatment with thiazolidiones within the last 6 months OAD treatment with three or more OADs within the last 6 months Acute insulin treatment for longer than 7 days in a row within the last 6 months Secondary diabetes Known maturity onset of diabetes of young (MODY) Known or suspected allergy to trial product or related products</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>